Australasian Biotechnology, Volume 9 Number 5, November/December 1999,
Autogen Limited - An Overview, Investee
Profile: Alchemia, BIO SHARES, The Deloitte Biotech Index
Code Number: AU99014
Autogen Limited - An Overview
Summary of Announcement
Agreement in principle for:
i) a placement of 15% of Company's shares at 25 cents per share
to Merck Lipha s.a.
ii) Merck Lipha s.a. to fund Autogen's Human Genetics Project
conducted by International Diabetes Institute _ US$1 million per
annum for 6 years.
iii) Jean-Noel Treilles, Chairman and Chief Executive Officer or
Merck Lipha s.a., to be appointed a Director of Autogen.
Investee Profile: Alchemia
Alchemia has attracted its third round of venture
capital funding. The commitment of $4 million from Coates Myer IIF
Fund brings the amount of equity capital raised by Alchemia to $8
Alchemia is developing a novel technology that enables the cost
effective manufacture of carbohydrates employing purely chemical
synthetic methodology. The immediate commercial applications of
Alchemia's technology are in the areas of pharmaceutical and
Covering Australian Biotechnology Stocks
The Deloitte Biotech Index
A Review of Key Biotechnology Stocks Listed on the
Australian Stock Exchange - December 1999 _ 1st Edition
The Deloitte Biotech Index focuses exclusively on 29 listed
biotechnology companies, excluding the "Blue Chip" healthcare
companies found in the ASX Healthcare and Biotech Index.
The biggest companies considered in the Index are Biota,
Cochlear, CSL, Novogen and Polartechnics.
Deloitte Biotech Index results include:
- From January 1997 to October 1998, the NASDAQ Biotech Index,
the ASX All Ordinaries Index, and the ASX Healthcare and Biotech
Index performed similarly.
- Since October 1998, the largest part of the indice increases
have occurred, led by the Deloitte Biotech Index and the NASDAQ
- Newly listed biotechnology stocks have generally been
The rapid evolution of the Australian biotechnology sector has
seen biotech stocks outstrip the ASX All Ordinaries Index more than
five-fold in Deloitte Touche Tohmatsu's inaugural Biotechnology
Copyright 1999 Australian Biotechnology Association Ltd.